Innoviva Inc has a consensus price target of $25.13 based on the ratings of 5 analysts. The high is $55 issued by Scotiabank on March 7, 2025. The low is $10 issued by Morgan Stanley on March 3, 2023. The 3 most-recent analyst ratings were released by Scotiabank, EF Hutton, and EF Hutton on March 7, 2025, May 10, 2023, and April 20, 2023, respectively. With an average price target of $33.33 between Scotiabank, EF Hutton, and EF Hutton, there's an implied 82.95% upside for Innoviva Inc from these most-recent analyst ratings.
1calculated from analyst ratings
Buy Now | Get Alert | |||||||
---|---|---|---|---|---|---|---|---|
03/07/2025 | Buy Now | 201.87% | Scotiabank | Louise Chen52% | → $55 | Initiates | → Sector Outperform | Get Alert |
08/01/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen52% | — | Reiterates | → Overweight | Get Alert |
07/30/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen52% | — | Reiterates | → Overweight | Get Alert |
06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen52% | — | Reiterates | → Overweight | Get Alert |
06/18/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen52% | — | Initiates | → Overweight | Get Alert |
05/10/2023 | Buy Now | 23.49% | EF Hutton | Constantine Davides37% | → $22.5 | Reiterates | → Buy | Get Alert |
04/20/2023 | Buy Now | 23.49% | EF Hutton | Constantine Davides37% | → $22.5 | Reiterates | → Buy | Get Alert |
03/03/2023 | Buy Now | -28.65% | Goldman Sachs | Chris Shibutani55% | $15 → $13 | Maintains | Neutral | Get Alert |
03/03/2023 | Buy Now | -45.12% | Morgan Stanley | Matthew Harrison62% | $13 → $10 | Maintains | Underweight | Get Alert |
03/03/2023 | Buy Now | 23.49% | EF Hutton | Constantine Davides37% | → $22.5 | Reiterates | → Buy | Get Alert |
01/24/2023 | Buy Now | -28.65% | Morgan Stanley | Matthew Harrison62% | $14 → $13 | Maintains | Underweight | Get Alert |
10/13/2022 | Buy Now | -23.16% | Morgan Stanley | Matthew Harrison62% | $13 → $14 | Maintains | Underweight | Get Alert |
08/08/2022 | Buy Now | -28.65% | Morgan Stanley | Matthew Harrison62% | $12 → $13 | Maintains | Underweight | Get Alert |
07/20/2022 | Buy Now | -12.18% | Goldman Sachs | Chris Shibutani55% | → $16 | Initiates | → Neutral | Get Alert |
07/15/2022 | Buy Now | -34.14% | Morgan Stanley | Matthew Harrison62% | $13 → $12 | Maintains | Underweight | Get Alert |
The latest price target for Innoviva (NASDAQ:INVA) was reported by Scotiabank on March 7, 2025. The analyst firm set a price target for $55.00 expecting INVA to rise to within 12 months (a possible 201.87% upside). 5 analyst firms have reported ratings in the last year.
The latest analyst rating for Innoviva (NASDAQ:INVA) was provided by Scotiabank, and Innoviva initiated their sector outperform rating.
There is no last upgrade for Innoviva
There is no last downgrade for Innoviva.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Innoviva, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Innoviva was filed on March 7, 2025 so you should expect the next rating to be made available sometime around March 7, 2026.
While ratings are subjective and will change, the latest Innoviva (INVA) rating was a initiated with a price target of $0.00 to $55.00. The current price Innoviva (INVA) is trading at is $18.22, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
A newsletter built for market enthusiasts by market enthusiasts. Top stories, top movers, and trade ideas delivered to your inbox every weekday before and after the market closes.